FILING ANALYSIS · MONDAY, NOVEMBER 16
Eloxx Pharmaceuticals, Inc. ELOX — 8-K: Results of Operations and Financial Condition
neutral
Eloxx Pharmaceuticals reported Q3 financial results and a business update, including dosing the first two patients in the global Phase 2b EXACT study and finalizing the protocol for the Phase 2 EXPRESS study, with cash and cash equivalents of $56.3 million as of September 30, 2026. No significant quantified surprises were disclosed in the filing.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →